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Inactivation of nuclear GSK3b by Ser389
phosphorylation promotes lymphocyte ﬁtness
during DNA double-strand break response
Tina M. Thornton1, Pilar Delgado2, Liang Chen3, Beatriz Salas1, Dimitry Krementsov1, Miriam Fernandez1,
Santiago Vernia4, Roger J. Davis4,5, Ruth Heimann6, Cory Teuscher1, Michael S. Krangel3, Almudena R. Ramiro2
& Mercedes Rinco´n1
Variable, diversity and joining (V(D)J) recombination and immunoglobulin class switch
recombination (CSR) are key processes in adaptive immune responses that naturally generate
DNA double-strand breaks (DSBs) and trigger a DNA repair response. It is unclear whether
this response is associated with distinct survival signals that protect T and B cells. Glycogen
synthase kinase 3b (GSK3b) is a constitutively active kinase known to promote cell death.
Here we show that phosphorylation of GSK3b on Ser389 by p38 MAPK (mitogen-activated
protein kinase) is induced selectively by DSBs through ATM (ataxia telangiectasia mutated)
as a unique mechanism to attenuate the activity of nuclear GSK3b and promote survival of
cells undergoing DSBs. Inability to inactivate GSK3b through Ser389 phosphorylation in
Ser389Ala knockin mice causes a decrease in the ﬁtness of cells undergoing V(D)J recom-
bination and CSR. Preselection-Tcrb repertoire is impaired and antigen-speciﬁc IgG antibody
responses following immunization are blunted in Ser389GSK3b knockin mice. Thus, GSK3b
emerges as an important modulator of the adaptive immune response.
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lycogen synthase kinase 3b (GSK3b) is a serine threonine
protein kinase abundantly expressed in all cells and
tissues1. GSK3b is present predominantly in the
cytoplasm, but also within the nucleus in response to pro-
apoptotic stimuli, although the function of nuclear GSK3b is
unclear2,3. GSK3b plays a critical role in determining the balance
between cell survival and death4. Deletion of GSK3b results in
lethality during embryonic development5. Unlike most kinases,
GSK3b is constitutively active and high levels of GSK3b activity are
associated with its role in promoting cell death4. To maintain cell
survival, active mechanisms are required to restrain GSK3b
activity6–8. Although cell death also plays an important role
during T- and B-cell development and the immune response, little
is known about the contribution of GSK3b to adaptive immune
responses. Pharmacological inhibitors that inhibit the activity of
both GSK3b and its closely related kinase GSK3a, have been shown
to interfere with thymocyte development at the double negative
(DN)3 stage in vitro9. Pharmacological inhibition of GSK3b/
GSK3a activity can reduce activation-induced cell death of CD4
cells10. In contrast, other studies have proposed that GSK3a is
primarily required for Th1 differentiation while GSK3b is primarily
required for Th17 differentiation11. It remains unknown whether
GSK3b plays a role in B-cell development or activation.
The best-characterized mechanism to repress GSK3b is the
phosphorylation of Ser9 primarily by Akt (refs 12,13). The ﬂexible
N terminus of GSK3b containing phospho-Ser9 acts as an
intrinsic competitive inhibitor of this kinase by folding into the
active site and competing with substrate binding14. High levels
of phospho-Ser9 GSK3b can be detected without external
stimulation in most cells of the immune system. However,
unexpectedly, GSK3b Ser9Ala knockin (KI) mice do not have a
defect in cell survival within the immune system or other
tissues15. This could be due to the compensatory effect by GSK3a
because increased activation-induced cell death of CD4 cells was
found in double mutant mice for GSK3b Ser9Ala and GSK3a
Ser21Ala (analogue to Ser9 in GSK3b)16. Increased GSK3 activity
in the Ser9Ala GSK3b/Ser21Ala GSK3a double mutant mice
promoted polarization of CD4 T cells to Th17 (ref. 17). No
studies, to the best of our knowledge, have reported the function
of GSK3b Ser9 inactivation in B cells.
We have identiﬁed that GSK3b can also be inactivated by
phosphorylation at Thr390(human)/Ser389 (mouse) by p38
mitogen-activated protein kinase (MAPK)18. Phosphorylation of
GSK3b at Ser389/Thr390 inactivates GSK3b to a similar degree as
Ser9 phosphorylation by Akt (ref. 18). While Akt, inhibits both
GSK3a and GSK3b, p38 MAPK does not phosphorylate GSK3a
(ref. 18). Interestingly, phosphorylation of Ser9 is ubiquitously
present under normal conditions, Ser389 phosphorylation is
restricted to the thymus, spleen and brain18. Thus, Ser389
phosphorylation represents an alternative pathway to restrain
GSK3b activity, but it remains unclear which stimuli require this
pathway and its function in cell death/survival. Here we show that
phosphorylation of GSK3b at Ser389/Thr390 is speciﬁcally induced
in response to DNA double-strand breaks (DSBs) and targets
nuclear GSK3b. We show that DSBs naturally generated during
V(D)J recombination in T- and B-cell receptors, and during class
switch recombination (CSR) of the immunoglobulin genes in
activated B cells19, inactivate nuclear GSK3b through Ser389
phosphorylation. We demonstrate that this pathway plays an
important role in the ﬁtness of T and B cells during DSB repair.
Results
Phosphorylation of GSK3b on Ser389 is induced by DSB. While
Ser9 phosphorylation of GSK3b is ubiquitous, phosphorylation of
GSK3b Ser389 occurs predominately in the thymus18. To
determine whether phosphorylation of Ser389 on GSK3b was
regulated during T-cell development, we examined phospho-
Ser389 GSK3b in DN and double positive (DP) thymocytes as well
as mature CD4 and CD8 cells. Interestingly, while total GSK3b
and phospho-Ser9 GSK3b did not change during development,
high levels of phospho-Ser389 GSK3b were detected in both DN
and DP thymocytes, but not in mature CD4 and CD8 cells
(Fig. 1a). Consistent with our previous results18, phosphorylation
of GSK3b on Ser389 correlates with the presence of active p38
MAPK (Fig. 1a).
Unlike peripheral naive T cells, both DN and DP thymocytes
are rapidly proliferating. To determine whether proliferation
promoted Ser389 phosphorylation of GSK3b, we activated
CD4 cells with anti-CD3 and anti-CD28 antibodies (Abs).
Although p38 MAPK was activated upon antigen stimulation,
no phospho-Ser389 GSK3b could be detected in activated CD4
cells indicating that proliferation does not induce phospho-Ser389
GSK3b (Fig. 1b). We have shown that p38 MAPK is activated
by V(D)J-mediated DSBs in thymocytes20. To investigate whether
phospho-Ser389 GSK3b was also triggered by DSBs, we examined
Ser389 phosphorylation of GSK3b in CD4 cells following
treatment with doxorubicin, a chemotherapeutic agent known
to generate DSBs21. Interestingly, doxorubicin elicited the
phosphorylation of GSK3b on Ser389 and this correlated with
the activation of p38 MAPK (Fig. 1c) and the induction of DSBs
as determined by the presence of gH2AX (Fig. 1d). The low dose
of doxorubicin that we used to induce DSBs did not cause
signiﬁcant death in CD4 cells (Fig. 1e). Similar to mouse CD4
cells, phospho-Thr390 was induced by doxorubicin in human
CD4 cells isolated from healthy controls (Fig. 1f).
To examine induction of phospho-Ser389 GSK3b in vivo
by DSBs, mice were irradiated and CD4 cells were puriﬁed
from spleen after exposure. X-irradiation induced Ser389
phosphorylation of GSK3b in CD4 cells (Fig. 1g). Ser389
phosphorylation was p38a MAPK dependent, since only
marginal levels of phospho-Ser389 GSK3b could be detected in
CD4 cells from T-cell conditional p38a MAPK knockout (p38c
KO) mice (Fig. 1g). To determine whether in vivo exposure to
radiation could induce Thr390 phosphorylation of GSK3b in
humans, we performed a pilot study with breast cancer patients
undergoing local radiotherapy as the ﬁrst regimen of therapy.
CD4 cells were isolated from peripheral blood collected before
beginning the treatment (base line). Patients received a daily dose
of radiotherapy for four consecutive days and CD4 cells were
isolated from blood collected 24 h after the last dose. While total
GSK3b levels remained unchanged by the treatment (Fig. 1h),
following radiotherapy phospho-Thr390 GSK3b was increased
over baseline in all four patients (Fig. 1h). We also examined
phospho-Thr390 GSK3b levels at two different time points
(4–6 days apart) in CD4 cells from healthy untreated volunteers,
and no changes over time were detected (Fig. 1i). Thus,
phosphorylation on Ser389/Thr390 regulates GSK3b selectively
in response to DSBs in both mouse and human.
V(D)J induces phospho-Ser389 GSK3b in the nucleus. DSBs
are also naturally produced in lymphocytes during V(D)J
recombination to generate the coding T-cell and B-cell receptor
genes22–24. V(D)J-mediated DSBs also trigger DNA damage and
repair responses23. At the DN3 stage of development, thymocytes
undergo V(D)J recombination of the TCRb locus to generate
a functional TCRb that provides a signal to terminate
recombination and promote differentiation to the DN4 stage.
Although the levels of total GSK3b were comparable between
DN3 and DN4 thymocytes, high levels of phospho-Ser389 were
only detected in DN3 thymocytes (Fig. 2a). To show that
phospho-Ser389 GSK3b was dependent on V(D)J recombination,
we examined DN3 thymocytes from wild-type (WT) and
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recombination activating gene (RAG)-deﬁcient mice that cannot
undergo V(D)J recombination due to the lack of RAG
recombinase25. Phospho-Ser389 GSK3b was much more
abundant in WT DN3 thymocytes than in RAG KO thymocytes
(Fig. 2b). To determine whether the increased level of phospho-
Ser389 GSK3b correlated with lower GSK3b activity, in vitro kinase
assays were performed. Lower GSK3b activity was present in WT
thymocytes than in RAG KO thymocytes (Fig. 2c). Ataxia
telangiectasia mutated (ATM) is a kinase activated by DSBs
including V(D)J-mediated DSBs and it is a major player in the
DSB-repair response26. To address whether phosphorylation of
GSK3b on Ser389 in DN3 thymocytes was triggered by DSBs or the
DSB-repair response we examined DN3 thymocytes in ATM KO
mice. Phospho-Ser389 GSK3b was diminished in DN3 thymocytes
from ATM KO mice (Fig. 2d). Consistent with previous studies
in vitro DSBs27, activated p38 MAPK was almost absent in ATM
KO thymocytes (Fig. 2d). In addition, analysis of phospho-Ser389
in DN3 thymocytes from T cell-conditional p38a MAPK KO mice
showed minimal levels compared to WT DN3 thymocytes
(Fig. 2e). In contrast, phospho-Ser9 GSK3b levels were not
affected (Fig. 2e). Thus, the restricted presence of GSK3b
phosphorylated on Ser389 in thymocytes in vivo is due to the
presence of V(D)J-induced DSB-repair response as a signalling
pathway to inactivate GSK3b through ATM and p38 MAPK.
We have previously shown that DSBs result in the selective
accumulation of p38 MAPK in the nucleus28. Phospho-Ser389
GSK3b localized selectively to the nucleus as shown by
immunostaining and confocal analysis in WT DN3 thymocytes
(Fig. 2f) and this was conﬁrmed by western blot analysis (Fig. 2g).
A similar nuclear distribution was found for human
phospho-Thr390 GSK3b in a human cancer cell line following
treatment with doxorubicin (Supplementary Fig. 1a), and this
was prevented by inhibiting ATM (Supplementary Fig. 1b). The
focal distribution of phospho-Ser389 in the nucleus of DN3
thymocytes was reminiscent of gH2AX foci at the DSBs generated
by V(D)J recombination at the TCRb locus. To determine
whether phospho-Ser389 GSK3b was recruited to the DSBs,
we performed co-immunostaining for both gH2AX and
phospho-Ser389 in DN3 thymocytes. Interestingly, the most
prominent phospho-Ser389 foci were adjacent to the gH2AX
foci (Fig. 2h). Thus, phosphorylation of GSK3b on Ser389 is
induced by V(D)J-mediated DSBs in thymocytes to preferentially
inactivate nuclear GSK3b.
Phospho-Ser389 GSK3b in B cells undergoing CSR-DSBs. CSR
of the Ig heavy chain locus in B cells initiated by activation-
induced cytidine deaminase (AID) also leads to the generation of
DSBs and involves components of the DNA repair
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Figure 1 | Inactivation of GSK3b by p38 MAPK is speciﬁcally induced by DSBs. (a) Western blot analysis of P-S389 GSK3b, P-S9 GSK3b, GSK3b, P-p38
MAPK and p38 MAPK in total thymocytes (T), double positive thymocytes (DP), double negative thymocytes (DN), mature CD4 Tcells and mature CD8 T
cells. Actin is shown as a loading control. (b) Mouse CD4 splenocytes were treated with media alone (Med) or stimulated with anti-CD3 and anti-CD28
Abs for 18 h and the levels of P-S389 GSK3b, GSK3b, P-p38 MAPK and p38 MAPK were determined by western blotting. Thymocytes are included as a
positive control. (c) Mouse CD4 splenocytes were treated with media alone (Med) or doxorubicin (Dox) for 18 h and the levels of P-S389 GSK3b, total
GSK3b, P-p38 MAPK and total p38 MAPK were determined by western blotting. (d) Mouse CD4 splenocytes were treated with media alone (Med) or
doxorubicin (Dox) for 18 h. Levels of P-S389 GSK3b, total GSK3b and gH2AX were determined by western blotting. GAPDH is shown as a loading control.
(e) Mouse CD4 splenocytes were treated with doxorubicin for 18 h and cell death was measured by AnnexinV staining and ﬂow cytometry (n¼ 3,
±s.e.m.). (f) Human CD4 cells were treated with media alone (Med) or doxorubicin (Dox) for 18 h. P-T390 GSK3b, total GSK3b and gH2AXwere examined
by western blotting. (g) WT and T-cell-speciﬁc p38a conditional knockout (cKO) mice were left unexposed or exposed to 4Gy of X-rays. After 1.5 h,
CD4 splenocytes were isolated and P-S389 GSK3b and total GSK3b assessed by western blotting. Actin is shown as a loading control. (h) Relative levels of
total GSK3b, P-T390 GSK3b and the relative ratio of P-T390 GSK3b to total GSK3b at baseline (BL) and after radiotherapy (Rad) in CD4 cells from breast
cancer patients, determined by the Odyssey system (n¼4). (i) Relative ratio of P-T390 GSK3b to total GSK3b in CD4 cells from healthy donors isolated in
two different days (baseline 1 and 2) for each subject (n¼ 3). *P valueo0.05 as determined by paired t-test. (a–g) Data are representative of three or more
independent experiments.
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machinery22,24,29. B cells were isolated from the spleen and
activated with lipopolysaccharide (LPS) and interleukin-4 (IL-4)
to induce CSR for the production of IgG1. Phospho-Ser389
GSK3b was induced following activation and correlated with
the presence of DSBs as determined by gH2AX (Fig. 3a). Analysis
of GSK3b activity in whole-cell lysates from activated B cells
showed lower activity at 48 h of activation correlating with
the induction of GSK3b Ser389 phosphorylation (Fig. 3b).
To demonstrate that AID-mediated DSBs were required to
induce phosphorylation of Ser389, we examined B cells from WT
and AID KO mice following stimulation. Correlating with a
signiﬁcant reduction in DSBs as determined by gH2AX (Fig. 3c),
phospho-Ser389 GSK3b was reduced in the AID KO B cells
compared with WT B cells (Fig. 3c). In contrast, levels
of phospho-Ser9 GSK3b were not affected in AID KO B cells
(Fig. 3c). We investigated the subcellular distribution
of phospho-Ser389 GSK3b in B cells undergoing CSR.
Phospho-Ser389 GSK3b was predominately in the nucleus of
activated B cells (Fig. 3d) while total GSK3b was present in both
the nucleus and cytosol (Fig. 3d). We also examined whether
phospho-Ser389 GSK3b was associated with CSR-generated DSBs
by co-immunostaining of gH2AX and phospho-Ser389 GSK3b.
Phospho-Ser389 foci were adjacent to the gH2AX foci in activated
B cells (Fig. 3e). Thus, DSBs generated in B cells undergoing CSR
selectively cause the inactivation of nuclear GSK3b through
phosphorylation on Ser389.
TCRb rearrangement is impaired in GSK3b Ser389 KI mice.
To determine the function of the phosphorylation of GSK3b at
Ser389/Thr390 relative to classical Ser9 phosphorylation, we
generated GSK3b-KI mice where Ser389 of GSK3b was replaced
with Ala to prevent the C-terminal phosphorylation of GSK3b
(Fig. 4a). Western blot analysis conﬁrmed the absence of
phospho-Ser389 GSK3b in thymocytes from homozygous
GSK3b-KI mice, while normal levels were present in hetero-
zygous GSK3b-KI mice (Fig. 4b). Ser9 phosphorylation of GSK3b
was not affected by the Ser389Ala mutation (Fig. 4b), showing that
these two residues represent independent pathways to regulate
GSK3b activity. To address the relative contribution of Ser389
phosphorylation to the overall GSK3b activity, we assayed GSK3b
activity in DN thymocytes and mature CD4 cells from WT and
Jβ1
WT KI WT KI
*
TR
BV
16
 
(re
lat
ive
 re
arr
an
ge
d a
lle
les
)
Jβ2
WT HET KI
P-S389
P-S9
GSK3β
ba
EcoR I Bgl II
Neo
Exon 11
S389AEcoR I Bgl II Bgl II BamH I
Neo
Targeting 
construct
Endogenous
allele
Targeted
allele
Targeted 
allele
Neo excised
e
D
N
3 
ce
ll
 
n
u
m
be
r (
×
 
10
5 )
KIWT KIWT
*
ic
TC
Rβ
+
 (%
)
f
KIWT
*
D
N
4 
ce
ll 
n
u
m
be
r (
×
 
10
5 )
R
at
io
 o
f D
N3
/D
N4
KIWT
*
WT KI
d
Ce
ll n
um
be
r (
×
 
10
6 )
g
TR
BV
 15
TR
BV
 19
TR
BV
 13
–2
Jβ1
WT KI WT KI
*
Jβ2
h
G
SK
3β
 ac
tiv
ity
(C
PM
 × 
10
3 )
*
KI KIWT WT
DN CD4c
150
150
100
100
50
50
Kl
 / 
W
T 
(%
)
TR
BV
19
(re
lat
ive
 r
e
a
rr
a
n
ge
d 
al
le
le
s)
1.5
1.0
1.0
10
1.0
0.5
0.0
0.8
8
0.8
0.6
6
0.6
0.4
4
0.4
0.2
2
0.2
0.0
0
0.0
3
2
1
0
0
0
6
4
2
0
3
2
1
0
40
30
20
10
0
4
3
3
2
2
1
1
0 0
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splenocyte from WTand GSK3b-KI mice were examined by in vitro kinase assays (n¼ 3). (d) Total number of thymocytes in WT (circles) and GSK3b-KI
mice (squares) (n¼ 8). (e) Total numbers of DN3 and DN4 thymocytes and the ratio of DN3/DN4 thymocytes from WT and GSK3b-KI mice (n¼6).
(f) Intracellular staining of TCRb and ﬂow cytometry analysis of DN3 thymocytes from WTand GSK3b-KI mice (n¼4). The percentage of iTCRb positive
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mean±s.e.m. *Po0.05 as determined by t-test. Data are representative of three or more independent experiments.
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GSK3b-KI mice. An increase in GSK3b activity was detected in
DN thymocytes from GSK3b-KI mice but no difference was
detected in mature CD4 cells correlating with the absence of
phospho-Ser389 GSK3b in mature CD4 cells (Fig. 4c). Thus,
phosphorylation of Ser389 contributes to restraining the activity of
GSK3b, independent of Ser9 phosphorylation.
S389A-GSK3b-KI mice were fertile and no developmental
abnormalities or gross alterations were detected under physio-
logical conditions. The percentage and number of mature CD4
and CD8 cells in the spleen and lymph nodes was not altered in
GSK3b-KI mice (Supplementary Fig. 2a–c). The fact that no
phospho-Ser389 GSK3b could be found in activated CD4 cells
(Fig. 1b) suggested that this pathway is not essential for activation
of CD4 cells. Analysis of proliferation of activated CD4 cells
from WT and GSK3b-KI mice showed no obvious difference
(Supplementary Fig. 3a). The number of cells recovered upon
activation was also comparable (Supplementary Fig. 3b) and there
was no difference in IL-2 production (Supplementary Fig. 3c).
Thus, correlating with the selective inactivation of GSK3b
through Ser389 phosphorylation in response to DSBs, this
pathway does not seem to be required for normal activation of
CD4 cells.
We next assessed the contribution of this pathway to
thymocyte development. No difference in the total number of
thymocytes (Fig. 4d), or in the numbers and percentage of DP
and single positive (SP) thymocytes (Supplementary Fig. 4a,b),
was detected between WT and S389A-GSK3b-KI mice. We
examined Va to Ja rearrangements in DP thymocytes to
determine if inability to inactivate GSK3b during Va–Ja
recombination could impair the TCRa repertoire. Analysis of
Va to Ja rearrangements using genomic DNA from isolated total
DP thymocytes suggested that GSK3b Ser389Ala mutation had no
effect in survival of DP thymocytes during TCRa recombination
(Supplementary Fig. 5). The number of total and percentage of
DN thymocytes in GSK3b-KI mice was not signiﬁcantly altered
(Supplementary Fig. 4a,b). However, examination of early
thymocyte development within the DN population showed a
reduction in the percentage and total number of DN4 thymocytes
in GSK3b-KI mice (Fig. 4e; Supplementary Fig. 4a). The
reduction of DN4 thymocyte number was associated with an
increase in the DN3/DN4 ratio (Fig. 4e). We examined whether
preventing inactivation of GSK3b by Ser389 phosphorylation
during TCRb-V(D)J recombination affected the number of DN3
thymocytes that successfully survive b-rearrangement. Intracel-
lular staining for TCRb in DN3 thymocytes showed a lower
frequency of DN3 thymocytes with successfully rearranged TCRb
in GSK3b-KI mice (Fig. 4f). Thus, inactivation of GSK3b through
Ser389 phosphorylation contributes to the ﬁtness of the DN3
thymocyte pool undergoing V(D)J recombination.
To determine whether this could result in an altered
distribution of TCRb speciﬁcities in mature T cells, CD4 cells
freshly isolated from the spleen of WT and GSK3b-KI mice were
used for TCRb spectrotyping analysis (Supplementary Fig. 6). We
detected a lower frequency of TRBV19 and TRBV13-2 in CD4
cells from GSK3b-KI mice relative to WT CD4 cells (Fig. 4f;
Supplementary Fig. 6). Other TCRb rearrangements (for
example, TRBV15) were not affected in any of the analysed
GSK3b-KI mice (Fig. 4g; Supplementary Fig. 6). In addition,
we performed quantitative analysis of a panel of Vb with Jb1
and Jb2 rearrangements using genomic DNA from WT and
GSK3b-KI DN thymocytes30. The frequency of TRBV19 with Jb2
rearrangement was lower in GSK3b-KI DN thymocytes (Fig. 4h),
but there was no statistically signiﬁcant difference for the
frequency of TRBV19 with Jb1 rearrangement. The TRBV16-
Jb2 rearrangement frequency was also reduced in GSK3b-KI
thymocytes, while the frequency of TRBV16-Jb1 was not
signiﬁcantly different, although a trend was observed (Fig. 4h).
The frequency of the other examined rearrangements of Vb
segment with Jb1 or Jb2 were not signiﬁcantly affected
(Supplementary Fig. 7). Thus, the inactivation of GSK3b by
phosphorylation on Ser389 promotes the survival of DN3
thymocytes during V(D)J recombination of the preselection
TCRb locus. Failure to inactivate GSK3b through this pathway
diminishes DN3 thymocyte ﬁtness and success in recombining
the TCRb locus leading to an altered TCRb repertoire.
In vivo antibody response in GSK3b Ser389KI mice is impaired.
Since GSK3b phosphorylation on Ser389 was induced in B cells by
CSR-generated DSBs, we investigated the effect of inactivation of
GSK3b through this pathway on the in vivo humoral response.
The percentage and the number of B cells in GSK3b-KI and WT
mice was comparable (Supplementary Fig. 8a,b). No signiﬁcant
difference was detected in the baseline levels of total IgM or IgG1
(Supplementary Fig. 8c,d). To examine the effectiveness of CSR in
an antigen-speciﬁc immune response, WT and GSK3b-KI
mice were immunized with ovalbumin (OVA). After 14 days,
immunized mice were euthanized and serum collected to assay
antibody responses. The level of serum OVA-speciﬁc IgM was
comparable in both WT and GSK3b-KI mice (Fig. 5a), as
expected considering that production of IgM isotype-Abs does
not require CSR. In contrast, the production of OVA-speciﬁc IgG,
which requires CSR, was largely abrogated in GSK3b-KI mice
(Fig. 5b). Moreover, IgG isotype analysis revealed reduced
OVA-speciﬁc IgG1 (Fig. 5c) and OVA-speciﬁc IgG2c (Fig. 5d) in
GSK3b-KI mice. Together, these results show for the ﬁrst time
that inactivation of GSK3b by phosphorylation of Ser389 is
essential for efﬁcient CSR and antibody production in vivo.
Since cytokines derived from CD4 cells play an important role
in promoting isotype switching of B cells, the impairment in IgG
production could be due to an impaired cytokine production
rather than to an intrinsic defect in B cells. To address this
possibility splenocytes from immunized WT and GSK3b-KI mice
were restimulated ex vivo with OVA, and the levels in the
supernatant of IL-4 and IFNg, two major cytokines that promote
IgG switching, were determined. The levels of both cytokines in
WT and GSK3b-KI cells were comparable (Fig. 5e,f), indicating
that T-cell helper responses are not impaired in GSK3b-KI mice.
Thus, the failure to undergo in vivo class switching and to mount
an antibody immune response in GSK3b-KI mice was most likely
due to an intrinsic defect in B cells due to inability to inactivate
nuclear GSK3b.
Phospho-Ser389 GSK3b promotes ﬁtness in response to CSR.
To demonstrate that the GSK3b Ser389Ala mutation in KI mice
interferes with efﬁcient CSR, we examined Ab production in
isolated B cells activated with LPS in the presence of IL-4 in vitro.
After 4 days, we examined the presence of IgG1 on the cell
surface of B cells, as a parameter for CSR. The frequency of
IgG1-expressing B cells from GSK3b KI mice was markedly
reduced (Fig. 6a). Thus, phosphorylation of GSK3b on Ser389 is
important for B cells undergoing CSR to successfully express
cell surface IgG1. To demonstrate that the low frequency of
IgG1-expressing B cells from GSK3b KI mice was due to the
inability of these cells to inactivate GSK3b during CSR, B cells
from WT and GSK3b-KI mice were activated in the presence
or absence of the pharmacological inhibitor of GSK3 (GSK3
Inhibitor X). The GSK3 inhibitor had no effect on the generation
of IgG1-expressing B cells from WT mice (Fig. 6b), supporting
the existence of endogenous mechanisms that suppress GSK3b
during CSR. Interestingly, the GSK3 inhibitor fully restored the
frequency of IgG1-expressing B cells from GSK3b-KI mice
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(Fig. 6b). In addition, inhibition of p38 MAPK by SB203580
signiﬁcantly reduced the frequency of IgG1-expressing WT B cells
but it had no effect on the frequency of IgG1-expressing B cells
from the GSK3b-KI mice (Fig. 6c) indicating that the effect of
p38 MAPK on CSR in B cells is mediated through Ser389
phosphorylation. Thus, inactivation of GSK3b through the Ser389
phosphorylation by p38 MAPK is important for successful Ab
isotype switching.
To determine whether the reduced frequency of IgG1-
producing B cells was due to impaired expansion, we performed
carboxyﬂuorescein succinimidyl ester (CFSE) labelling. No
difference in proliferation was observed between WT and
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Figure 6 | Inactivation of GSK3b by p38 MAPK-mediated phosphorylation on Ser389 is required for B cells to survive the DNA damage response
triggered by CSR. (a) Puriﬁed B cells from WT and GSK3b-KI mice (n¼ 3) were activated for four days with LPS and IL-4 and the surface level of IgG1
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examined ﬂow cytometry analysis. (e) B cells from WTand GSK3b-KI mice (n¼4) were activated for three days and viability determined by trypan blue
staining. Percentage of cell survival relative to activated WT B cells is provided (% relative to WT cells). (f) B cells from WT and GSK3b-KI mice (n¼4)
were activated for three days and cell death was measured by AnnexinV staining and ﬂow cytometry analysis. Percentage of AnnexinV positive cells for
each cell type is shown. (g) B cells from WT and GSK3b-KI mice (n¼ 3) were activated for three days and stained for AnnexinV, B220 and IgG1. The
percentage of AnnexinVþ cells in the B220þ IgGþ and B220þ IgG- populations are shown. *P valueo0.05 as determined by t- test. Data are shown as
mean±s.e.m. and are representative of three or more independent experiments.
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GSK3b-KI B cells (Fig. 6d). Similarly, there was no difference in
cell cycle proﬁles between WT and GSK3b-KI B cells following
activation (Supplementary Fig. 9). However, there was a
signiﬁcant reduction in survival of GSK3b-KI B cells relative to
WT B cells based on cell recovery (Fig. 6e). Annexin V staining
conﬁrmed increased cell death in activated GSK3b-KI B cells
(Fig. 6f; Supplementary Fig. 9b). Increased death in activated
GSK3b-KI B cells was also supported by analysis of cell
size (Supplementary Fig. 9c) and live/dead blue staining
(Supplementary Fig. 9d,e). Together, these results show that
GSK3b Ser389Ala mutation decreases the ﬁtness of B cells
while undergoing CSR, compromising their ability to produce
antibodies.
Mcl-1 degradation causes necroptosis in KI B cells. One of the
mechanisms by which GSK3b can mediate cell death is by
phosphorylation of b-catenin in the cytosol, leading to the rapid
degradation of b-catenin by APC complex31,32. However, b-
catenin levels were comparable in activated GSK3b-KI B cells and
WT B cells (Fig. 7a). GSK3b also promotes the degradation of
Mcl-1 through phosphorylation on Ser159 (mouse Ser140)33. In
response to DSBs, Mcl-1 accumulates in the nucleus, where it
associates with gH2AX and DSB34,35, and it is required for DSB
response through different mechanisms35. Mcl-1 deﬁciency
results in increased genomic instability and it is essential for
B-cell survival following activation34–36. Interestingly, western
blot analysis showed that the levels of Mcl-1 were almost
undetectable in activated GSK3b-KI B cells (Fig. 7b). To rule out
that the reduced levels of Mcl-1 were not the result of increased
mitochondrial dysfunction in GSK3b-KI B cells we examined the
levels of other Bcl2 family members. The levels of Bcl2, BclX
(anti-apoptotic) as well as Bid, Bax and Bad (pro-apoptotic) were
not different between WT and GSK3b-KI B cells (Fig. 7c). Mcl-1
has been shown to regulate PUMA37 that also mediates apoptosis
in response to DNA damage38. PUMA was highly expressed in
thymocytes exposed to irradiation (Fig. 7d), but only marginal
levels could be detected in either WT or GSK3b-KI B cells
(Fig. 7d). We also examined mitochondria integrity by staining
with Mitotracker (Fig. 7e), as well as mitochondrial membrane
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potential by staining with TMRE (Fig. 7f), but no differences
between WT and GSK3b-KI B cells were detected. The reduction
of Mcl-1 in GSK3b-KI B cells therefore was not associated with
dysfunctional mitochondria.
These results also suggested that increased death found in
GSK3b-KI B cells might not be through apoptosis mediated by
mitochondria and caspase-3. Analysis of caspase-3 activation
showed comparable levels of active caspase-3 (cleaved form) in
activated WT and GSK3b-KI B cells (Fig. 7g). In addition, most of
the Annexin V-positive cells were propidium iodide positive
(Supplementary Fig. 10), suggesting the presence of other
death pathways. DNA damage has also been shown to trigger
necroptosis, a mitochondria-independent mechanism of
death39,40. RIPK1, the most upstream component of the
ripoptosome pathway, is normally cleaved to prevent the
formation of the necrosome and death by necroptosis41.
Cleaved RIPK1 was present in activated WT B cells, but only
low levels could be detected in GSK3b-KI B cells (Fig. 7g).
In vitro, blocking of caspase-8 promotes death by necroptosis42.
Negligible levels of cleaved caspase-8 were detected in both
activated WT and GSK3b-KI B cells (Supplementary Fig. 11a),
suggesting that there is minimal activity of caspase-8 in activated
B cells overall. As a positive control for cleaved caspase-8 we
used activated B cells treated with Fas ligand known to trigger
caspase-8 cleavage (Supplementary Fig. 11a). Thus, the increased
death found in activated B cells that fail to inhibit GSK3b could
be mediated by necroptosis. We therefore examined the
effect of necrostatin-1s, a selective inhibitor of necroptosis
through RIPK1 (ref. 43). WT and GSK3b-KI B cells were
activated. Necrostatin-1s was added after 2 days of activation,
when DSBs and phospho-Ser389 GSK3b were detected (Fig. 3)
and before differences in survival were observed (Supplementary
Fig. 11b). Cell survival was determined 24 h after treatment with
necrostatin-1s (day 3 of activation). Interestingly, treatment with
necrostatin-1 restored survival of activated GSK3b-KI B cells
(Fig. 1h) Similar results were obtained adding necrostatin-1s at 24
and 36 h following activation (Supplementary Fig. 11c). During
necroptosis active RIPK1 activates the downstream kinase RIPK3,
and RIPK3 then mediates the phosphorylation of MLKL, one of
the mediators of necroptosis that translocates to the membrane,
causes membrane rupture and death40,44,45. Increased levels in
phospho-MLKL were detected in GSK3b-KI B cells (Fig. 7i).
Thus, inactivation of nuclear GSK3b by phosphorylation on
Ser389 is a mechanism to minimize necroptosis-mediated cell
death of B cells during CSR.
Since the subcellular localization of Mcl-1 in activated B cells
has not been addressed, we performed immunostaining for Mcl-1
and confocal microscopy analysis. Abundant levels of Mcl-1 were
present both in the cytosol and the nucleus of WT B cells (Fig. 7j).
In contrast, the remaining Mcl-1 levels in GSK3b-KI B cells were
almost exclusively outside the nucleus (Fig. 7j). Treatment of
GSK3b-KI B cells with the GSK3 inhibitor restored Mcl-1 levels
in the nucleus to those in WT B cells (Fig. 7j). In addition,
western blot analysis for Mcl-1 showed comparable levels in the
mitochondrial fraction, however, levels of Mcl-1 in the nuclear
fraction were drastically decreased in GSK3b-KI B cells (Fig. 7k).
To address whether the decreased nuclear levels of Mcl-1
contribute to the impaired survival of GSK3b-KI B cells we
ectopically expressed WT Mcl-1, or a previously described
mutant form of Mcl-1 (mMcl-1) where Ser140 is replaced by
Ala (Ser140Ala)46 and therefore it cannot be phosphorylated by
GSK3b and degraded33,46. Thus, WT Mcl-1 will still be degraded
by GSK3b Ser389Ala in KI B cells, but the mMcl-1 mutant
should be protected from degradation. Accordingly, WT Mcl-1
expression did not increase survival of GSK3b-KI B cells relative
to empty vector (Fig. 7l). In contrast, expression of Ser140Ala
mMcl-1 restored survival of GSK3b-KI B cells (Fig. 7l). Efﬁciency
of transduction with both retroviruses in GSK3b-KI B cells was
comparable (Supplementary Fig. 12a), and the total levels of
Mcl-1 expression as determined by qRT–PCR (quantitative PCR
with reverse transcription) was also comparable (Supplementary
Fig. 12b). Therefore, nuclear Mcl-1 present in activated B cells is
selectively targeted by GSK3b for degradation, and inactivation of
GSK3b through phosphorylation on Ser389 is necessary to sustain
Mcl-1 levels and ﬁtness of B cells undergoing CSR.
Discussion
DSBs are dangerous types of DNA damage because they create
genomic instability and impair cell survival. However, V(D)J and
CSR-mediated DSBs are essential for generating the diversity of
our adaptive immune system. Here we identify phosphorylation
of GSK3b at Ser389/Thr390 as a survival pathway that is triggered
speciﬁcally by DSBs, in contrast to Ser9 phosphorylation that is
used as a general mechanism to restrict GSK3b activity. In
addition, we show that Ser389/Thr390 phosphorylation regulates
GSK3b in the nucleus where GSK3b associates with gH2AX in
response to DSBs. The selective induction of Ser389 phosphoryla-
tion by DSBs could explain the selective tissue distribution of this
phosphorylation, mainly in the thymus and spleen. Interestingly,
phospho-Ser389 is also abundant in brain18 where recent studies
have reported the presence of DSBs caused by normal brain
activity and stress47. We show here that the inability of cells
to inactivate GSK3b through Ser389 phosphorylation (GSK3b
Ser389Ala mutant cells) causes a decline in the ﬁtness of cells
undergoing DSB induced by V(D)J recombination or CSR. We
have also shown that failure to inactivate GSK3b through Ser389
phosphorylation in CD4 cells from GSK3b KI mice makes these
cells more sensitive to death caused by low dose of irradiation
(Supplementary Fig. 13a) or the chemotherapeutic drug
doxorubicin (Supplementary Fig. 13b,c). Thus, phosphorylation
of GSK3b on Ser389 in response to chemotherapy or radiotherapy
may have implications in the treatment of cancer.
This study reveals a role of GSK3b in B cells. We demonstrate
that inactivation of GSK3b by Ser389 phosphorylation upon
activation of B cells is required optimum survival during CSR and
for in vivo antigen-speciﬁc IgG antibody production. Suppression
of p53 by BCL6 has been reported to be a prosurvival signal in
germinal centre (GC) B cells48,49. In addition, both Mcl-1 (ref. 36)
and c-Myc50 are also essential for GC B-cell survival although it is
unclear how they are regulated. Our studies show that
inactivation of nuclear GSK3b by phosphorylation at Ser389 is
essential for the stabilization of the nuclear pool of Mcl-1. While
Mcl-1 localizes predominantly in the mitochondria it is also
found in the nucleus speciﬁcally in response to DSBs34,35.
GSK3b has been shown to increase Mcl-1 instability through
phosphorylation on Ser140 (ref. 46). Here we show that only
Ser140Ala mutant Mcl-1, but not WT Mcl-1, restores viability of
activated GSK3b-KI B cells. Thus, preventing phosphorylation of
Mcl-1 on Ser140 by nuclear GSK3b could be a key mechanism
to prolong survival during the repair of DSBs. Interestingly, our
studies also reveal necroptosis as an important mechanism of
death in B cells late during activation. DSBs are one of
the reported stimuli that can promote necroptosis51,52.
Inactivation of GSK3b through phosphorylation of Ser389
restrains necroptosis, promoting successful CSR and antibody
production. Future studies will be needed to address if the
crosstalk between GSK3b, Mcl-1 and necroptosis is also observed
in other DSB responses.
Our studies show that inactivation of GSK3b by Ser389
phosphorylation contributes to the survival of DN3 thymocytes
undergoing TCRb rearrangement, leading to a reduction in the
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number of DN4 thymocytes. Similar phenotypes have been also
described for mice deﬁcient in ATM, Nbs1 gH2AX, that have
impaired DSB repair responses53–55. A number of parameters
such as chromatin environment inﬂuence the frequency of the
TCRb V-DJ rearrangements before TCRb selection30. Impaired
survival of thymocytes undergoing speciﬁc TCRb rearrangements
could also affect the TCRb repertoire. Here we show decreased
frequencies of some TCRb rearrangements in GSK3b-KI mice.
TCRb repertoire is also impaired in the absence of ATM through
an antigen selection-independent mechanism54. Our data suggest
that inactivation of GSK3b by Ser389 is not essential for survival
of DP thymocytes during TCRa recombination. Sequential
recombination of D to J and DJ to V of the TCRb locus may
need additional survival signals. Likewise, the secondary
recombination event in the TCRb locus between V to DJ2, after
an out of frame V to DJ1 rearrangement, may be more dependent
on survival signals, as suggested by our results.
In summary, our study reveals for the ﬁrst time a speciﬁc
pathway for regulation of nuclear GSK3b in response speciﬁcally
to DSBs, including V(D)J recombination and CSR (Fig. 8). We
also demonstrate that this inactivation pathway of GSK3b is
essential for ﬁtness of cells undergoing DSBs and therefore has an
important role in the adaptive immune response.
Methods
Mice. For the generation of GSK3b KI mice, a targeting vector constructed
(InGenious Targeting Laboratory, Inc.) from a 9.27 kb region subcloned from the
C57BL/B6 BAC clone (RPCI-23: 454D5) into the vector backbone (2.4 kb pSP7
(Promega)). The long homology arm extended 6.36 kb 50 to the T-G point
mutation in exon 11 and the LoxP/FRT ﬂanked Neo cassette was inserted 511 bp
30 to the T-G point mutation. The short homology arm extended 2.40 kb 30 to the
loxP ﬂanked Neo cassette. The targeting vector was constructed using Red/ET
recombineering technology and the T-G point mutation was created by overlap
PCR. The linearized targeting vector electroporated into BA1(C57BL/6 129/
SvEv) hybrid embryonic stem cells. Following G418 selection, surviving clones
were screened by PCR to identify homologous recombinant clones for injection
into blastocysts. The neomycin cassette was excised by breeding heterozygous
GSK3b KI mice with EIIa-cre mice56 (Jackson Laboratories). GSK3b KI mice
were backcrossed to C57BL/6 at least seven generations. Wild-type C57BL/B6,
129S6/SvEvTac ATM KO (ref. 57), and B6.129S7 Rag1 KO (ref. 25) mice were
purchased from Jackson Laboratories. C57BL/B6 p38a conditional knockout (p38
cKO) mice were generated by crossing the homozygous ﬂoxed p38amice58 (Riken)
with C57BL/B6 T-cell-speciﬁc Lck-Cre transgenic mice59 (Taconic). Balb/c AID
KO mice were derived from AID KO mice60. For studies with DN3 thymocytes,
3–4-week old male and female mice were used. Male and female mice 8–16 weeks
of age were used in all other experiments. Mice in each experiment were age and
sex matched. All procedures that involved mice were approved by the University of
Vermont’s institutional guidelines for animal care.
Human samples. Healthy volunteers and patients who agreed to donate peripheral
blood signed a consent form that was approved by the Institutional Review Board
of The University of Vermont. Breast cancer patients who were undergoing
local radiation therapy as a ﬁrst regimen of therapy and had not received any
chemotherapy or hormonal based-therapy were enroled in the study. Blood was
drawn before beginning radiotherapy treatment (baseline), and after the last of the
four consecutive doses of the ﬁrst cycle with radiotherapy (X-rad). CD4 T cells
were puriﬁed from peripheral blood mononuclear cells by positive selection using
the CD4 MACS kit (Miltenyi Biotec) as recommended by the manufacturer.
X-ray exposure. For in vivo X-radiation (RadSource 2000), mice were exposed
to the indicated dose and sacriﬁced following a 1.5 h recovery period. For
X-irradiation of cells, cells were exposed to the indicated dose and harvested 18 h
post exposure. Freshly isolated thymocytes were exposed to 5Gy and allowed to
recover for 1 h before harvest.
Immunizations. Mice were immunized subcutaneously with OVA (Sigma) in CFA
(Sigma) and euthanized after 14 days. Blood was collected and allowed to coagulate
in the refrigerator in Microtainer Serum Separator tube (BD). Serum was isolated
by centrifugation. For ELISA to detect OVA-speciﬁc Ig, plates were coated with
2mgml 1 OVA. Antibody levels in serially diluted serum samples were analysed
with HRP-conjugated antibodies (1:4,000) speciﬁc for mouse IgM (1021-05),
IgG (1030-05), IgG1 (1070-05), and IgG2c (1079-05) (SouthernBiotech) following
manufacture’s recommended protocols. For ex vivo cytokine production,
splenocytes were isolated 14 days following OVA-CFA immunization and cultured
in the presence of OVA (100 mgml 1). ELISAs were performed with puriﬁed
anti-IFNg (Biolegend 505707) and anti-IL-4 mAb (Biolegend 504102) as capture
antibodies, the corresponding biotinylated anti-IFNg (Biolegend 505804,
1 mgml 1)and anti-IL-4 mAb (BD Biosciences 554390 1 mgml 1), horseradish
peroxidase-conjugated streptavidin (Sigma), and the TMB microwell peroxidase
substrate and stop solution (Kirkegaard & Perry Labs, Inc.) according to the
recommended protocol (Biolegend). Recombinant mouse IFNg and IL-4 (R&D
Systems) was used as standards.
Western blot analysis. Whole-cell extracts were prepared in Triton lysis buffer
(20mM Tris (pH 7.4), 137mM NaCl, 2mM EDTA, 1% Triton X-100, 10%
glycerol, 25mM b-glycerophosphate and 1mM sodium vanadate) supplemented
with mammalian protease inhibitor cocktail (Sigma). Nuclear and cytosolic extracts
were prepared as follows: fresh cell pellet was resuspended in 400ml cold buffer A
(10mM HEPES pH 7.9, 10mM KCI, 0.1mM, EDTA, 0.1mM EGTA, 1mM DTT
and 0.5mM PMSF) supplemented with mammalian protease inhibitor cocktail
(Sigma). After 15min on ice, 25 ml of a 10% solution of IGEPAL (Sigma) was added
while vigorously vortexing for 10 s. The homogenate was centrifuged for 30 s at
13,000 r.p.m. The supernatant containing cytoplasm was transferred to a fresh tube.
The nuclear pellet was resuspended in 50 ml ice-cold nuclear lysis buffer (20mM
HEPES pH 7.9, 0.4M NaCl, 1mM EDTA, 1mM EGTA,1mM DTT and 1mM
PMSF) supplemented with mammalian protease inhibitor cocktail (Sigma) and the
tube is vortexed at 4 C for 15min. The nuclear extract was centrifuged for 5min at
13,000 r.p.m. Mitochondrial extracts were prepared using the Mitochondrial
Fractionation Kit (Active Motif).
Protein lysates were resolved by SDS–polyacrylamide gel electrophoresis and
transferred to PVDF membrane (Millipore). All primary antibodies were used
at 1:1,000. Anti-actin (SC-1616), anti-p38 MAPK (SC-7972), anti-GAPDH
(SC-25778, anti-histone H1 (SC-8030), anti-PUMA (SC-377015) and anti-GSK3b
(SC-9166) were purchased from Santa Cruz Biotechnology. Anti-phospho-p38
MAPK (#9215), anti-gH2AX( #2577), anti-CoxIV (#4844), anti-Caspase-3 (#9662),
and anti-phospho-Ser9 GSK3b (#9323) were purchased from Cell Signaling.
Anti-Bcl2 (B46620), anti-Bclx (B61220), anti-Bid (B21320), anti-Bax (B73520),
anti-Bad (B36420) and anti-RIPK1 (610459) were purchased from BD Biosciences.
Anti-Mcl (600-401-394) was purchased from Rockland. Anti-phospho-MLKL
(196436) was purchased from Abcam. Anti-Caspase-8 (ALX-804-488-C100)
was purchased from Enzo. Anti-phospho-Ser389 was previously described18.
Anti-phospho-Thr390 GSK3b rabbit polyclonal antibody was generated
(Proteintech, Inc.) using N-C-ARIQAAASphospho-TPTNATA for immunization.
Anti-rabbit HRP (Jackson ImmunoResearch Laboratories 111-035-144, 1:10,000),
anti-mouse HRP (Jackson ImmunoResearch Laboratories 115-035-166, 1:10,000),
anti-rat HRP (Dako P0450, 1:1,000) and anti-goat HRP (Santa Cruz Biotechnology
SC-2056, 1:10,000) were used as secondary antibodies. For quantitative western
blot analysis of human samples, secondary IRD-tagged antibodies (800 IRDye and
680 IRDye; Li-COR) were used and western blot signals were analysed with an
Odyssey Li-COR laser scanning and imaging system (Li-COR, v3.0). Images
have been cropped for presentation. The uncropped images are shown in the
Supplementary Figs 15–18.
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Figure 8 | DSBs trigger the inactivation of GSK3b by p38 MAPK to
promote the accumulation of the prosurvival factor Mcl-1 leading to
enhanced cell ﬁtness. Schematic model for the pathway.
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GSK3b kinase activity assays. GSK3b was immunoprecipitated from the
indicated protein lysates with anti-GSK3b (Cell Signaling #9315) and protein A/G
PLUS agarose beads (Santa Cruz SC2003). For kinase assays, reactions were
incubated at 30 C in kinase buffer (Cell Signaling) supplemented with 1mM ATP
containing [g-32P] ATP and GSM substrate peptide (62.5mM) (Upstate). Reactions
were terminated by spotting onto P81 ﬁlters. Filters were washed extensively and
counted in a scintillation counter.
Cell culture. MCF-7 cells were maintained in RPMI (Lonza) supplemented
with 5% FBS, L-glutamine, penicillin and streptomycin (Invitrogen). Cells were
stimulated with doxorubicin (0.1 mgml 1) (Sigma) for 18 h. For all inhibitor
treatments, SB203580 (5mM), ATM inhibitor (5 mM) and GSK3 inhibitor X
(2.5mM; Calbiochem) pretreatment was performed at 37 C for 30min, before cell
stimulation. CD4 T cells were isolated from spleens by positive selection using
anti-CD4 magnetic beads (Miltenyi). The purity obtained was about 90–95%
(Supplementary Fig. 14A). CD4 cells were treated with doxorubicin (0.1 mgml 1)
or stimulated with plate bound anti-CD3 (5mgml 1) and soluble anti-CD28
(1mgml 1) mAbs (BD Biosciences) for 18 h before analysis. B cells were isolated
from spleens by positive selection with anti-CD19 magnetic beads (Miltenyi).
Purity for B cells obtained using this approach was 95% (Supplementary Fig. 14B).
B cells were stimulated with LPS (25mgml 1; Sigma) and recombinant mouse Il-4
(10 ngml 1; PeproTech) for the indicated period of time. Necrostatin-1s (10 mM;
BioVision) was added at the indicated time following activation. After 2 days of
activation, B cells were treated for 3 h with human recombinant ﬂag-tagged Fas
Ligand (200 ngml 1) and anti-Flag antibody (2mgml 1; Sigma) for caspase-8
activation positive control. Recombinant retroviruses were prepared by transient
transfection of plasmids in 293T cells. B cells activated for 24 h were transduced
with retrovirus produced using either pBABE-IRES-Puro empty vector, wt Mcl-1
or a mMcl-1 Ser140Ala expression vector. Retroviral transduction efﬁciency was
examined by real-time qPCR using equal amount of DNA isolated from transfected
cells and measuring retroviral vector Mcl-1 DNA. Total mRNA Mcl-1 levels were
determined by real-time qRT–PCR using total RNA from transduced cells and
18S expression as housekeeping gene. Taqman Mcl-1 AOD (assay on demand)
primers/probe set was used for both qPCR and qRT–PCR (Applied Biosystems).
Flow cytometry. Thymocyte and T-cell subpopulations were examined after cell
surface staining with anti-CD4 (Biolegend 100530, 1:200), CD8 (Invitrogen
MCDO817, 1:200), CD25 (Biolegend 102006, 1:200) and anti-CD44 antibodies
(BD Biosciences 559250, 1:200) by ﬂow cytometry (LSR II, BD Biosciences). DN3
and DP cells were sorted after four colour staining (FacsAria, BD Biosciences).
DN cells were obtained by depletion of CD4- and CD8-positive cells using
magnetic beads (Qiagen). Thymocytes were stained for surface antigens and
then permeabilized with 0.3% saponin to allow detection of intracellular TCRb
(Biolegend 109222, 1:200). Cells from spleen, lymph nodes and puriﬁed B cells
were treated with FC Block (BD Biosciences 553141, 1:100) before staining surface
antigens. Cell surface IgG1 was analysed by ﬂow cytometry after surface staining
with anti-B220 (553088, 1:200) and anti-IgG1 (553441, 1:200; BD Biosciences).
Annexin V (Biolegend) staining with and without propidium iodine (Sigma)
was performed as recommended by the manufacturer. CFSE (Molecular Probes)
labelling was performed according to the manufacturer’s instructions. Cells
(1 107 cells per ml) were incubated with 2.5 mM CFSE in 0.05% BSA in PBS at
37 C for 10min and activated to stimulate proliferation. For cell cycle analysis,
cells (106 cells) were resuspended in low salt staining solution (3% (w/v)
polyethylene glycol PEG 8000, 50 mgml 1 propidium iodide, 180Uml 1 RNase
A, 0.1% Triton X-100, 4mM sodium citrate) and incubated on ice for 30min.
An equal volume of high salt solution (3% (w/v) polyethylene glycol PEG 8000,
50mgml 1 propidium iodide, 180Uml 1 RNase A, 0.1% Triton X-100 and
400mM sodium chloride) was added just before analysis by ﬂow cytometry.
Mitochondrial functional analysis was performed by staining with MitoTracker
(Life Technologies) or TMRE (Molecular Probes) for 20min at 37 C as
recommended by the manufacturer.
Confocal microscopy. For staining of MCF-7 cells and lymphocytes, cells were
ﬁxed, permeabilized and stained with primary antibody followed by ﬂuorescently
labelled secondary antibody. The primary antibodies used included the rabbit
anti-phospho-Ser389 (1:500) or anti-phospho-Thr390 (1:250) GSK3b and
anti-Mcl-1 (1:200) polyclonal antibodies described above. Mouse monoclonal
anti-gH2AX (Millipore 05–636, 1:300) was used for co-staining with phospho-S389
GSK3b. Secondary antibodies used were Alexa Fluor 568 anti-rabbit (A11036,
1:500) and Alexa Fluor 488 anti-mouse (A11029, 1:500) highly adsorbed antibodies
(Invitrogen). Topro-3 (Invitrogen) was used as a nuclear stain. Images of ﬁxed cells
were acquired on a Zeiss LSM-510.
Tcrb sprectrotyping. CD4 T cells were isolated from spleens by positive selection
using anti-CD4 magnetic beads (Miltenyi). Spectrotyping was carried out using the
SuperTCRExpress CDR3 Size Diversity Determination Kit as per manufactures’
instructions (BioMed Immunotech).
Tcra rearrangement. Tcra rearrangement was analysed by real-time PCR using a
QuantiFast SYBR Green PCR kit (Qiagen) and a Roche LightCycler 480. Primers
are listed in (Supplementary Table 1). PCR reactions for individual experiments
were run in duplicate using the following ampliﬁcation program: 95 C for 5min,
followed by 45 cycles of 95 C for 10 s and 62 C for 30 s. Results were normalized
to signals for the Tcra enhancer (Ea).
Tcrb rearrangement. Tcrb rearrangement was analysed by real-time PCR using
PerfeCta SYBRGreen SuperMix (Quanta Biosciences) and AB 7500 Fast Real-time
PCR System (Applied Biosystems). Primers are listed in (Supplementary Table 2).
PCR reactions for individual experiments were run in duplicate using the following
ampliﬁcation program: 95 C for 2min, followed by 40 cycles of 95 C for 15 s,
60 C for 1min and 72 C for 1min. Results were normalized to signals for the
MAPK14 gene.
Statistical analysis. Statistical signiﬁcance between two groups was determined
using Prism (Graphpad), by standard Student t-test. Statistical signiﬁcance among
more than two groups was determined by one-way ANOVA. For all analyses,
Pr0.05 was considered signiﬁcant.
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